An institutional alternative investor based in France manages an internal division dedicated exclusively to direct investments in the life sciences. The firm is currently investing out of its 4th fund which recently closed at $250 million bringing its total assets under management to over $1 billion. The firm invests anywhere from $2 to $20 million into its portfolio companies and is capable of investing into approximately 10 companies from its 4th fund. The firm looks to act as the lead investor into companies providing equity capital and assuming approximately a 20% shareholding. The firm is looking to invest primarily in companies based in Europe but has 20% of its portfolio dedicated to global investments.
The firm is looking for companies developing Therapeutics, Medical Devices and Molecular Diagnostics. The firm is open to the spectrum of subsectors and indications; however it is reluctant to allocate to cell or gene therapy and has significant experience in diabetes so companies targeting this indication are of special interest. The firm also is willing to consider companies targeting orphan indications. For therapeutics companies the firm is looking for opportunities in early Phase I or later. For medical devices the company must have some in human data to be considered.
The firm looks to have strong involvement in the firm’s management team and hold positions on the company’s Board. The firm looks to hold investments for 2-6 years before selling shares, generally to a large company that will finalize the products commercialization. Companies located outside of Europe are often recommended and advised by the firm on opening up subsidiaries in Europe using the firm’s vast European network
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment